Corcept Therapeutics Incorporated (CORT)

Operating return on assets (Operating ROA)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Operating income (ttm)	US$ in thousands	107,282	98,112	98,869	100,718	112,634	126,799	131,097	131,608	124,477	118,323	106,810	110,129	128,202	132,708	140,993	130,364	111,609	101,491	91,456	87,457
Total assets	US$ in thousands	621,517	594,022	524,625	617,848	583,430	533,255	496,364	468,123	423,756	585,399	568,480	552,398	571,731	534,125	497,823	445,494	412,312	367,022	328,679	320,212
Operating ROA		17.26%	16.52%	18.85%	16.30%	19.31%	23.78%	26.41%	28.11%	29.37%	20.21%	18.79%	19.94%	22.42%	24.85%	28.32%	29.26%	27.07%	27.65%	27.83%	27.31%

December 31, 2023 calculation

Operating ROA = Operating income (ttm) ÷ Total assets
= $107,282K ÷ $621,517K
= 17.26%

The operating return on assets (operating ROA) of Corcept Therapeutics Inc has shown some fluctuations over the past eight quarters. The trend indicates that the company's ability to generate operating income from its assets has been varying. The operating ROA ranged from 16.30% to 28.11% during this period.

In the most recent quarter, Q4 2023, the operating ROA was 17.26%, showing a slight increase from the previous quarter at 16.52% in Q3 2023. Prior to this, the operating ROA had been relatively stable, with higher levels observed in Q4 2022 at 19.31%, Q3 2022 at 23.78%, Q2 2022 at 26.41%, and Q1 2022 at 28.11%.

The decrease in operating ROA over the past few quarters may indicate a decrease in the company's ability to generate profits from its operating assets. However, it is essential to conduct a deeper analysis to understand the reasons behind these fluctuations and evaluate the company's operational efficiency and profitability.